- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - 666-888-0000
- info@tersanpharm.com
- info@tersanpharm.com
- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - Contact Us
Jun2022
Tersan Pharmaceuticals Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Tersan Pharmaceuticals Ltd and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Tersan Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Mar2022
Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Tersan, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.
Feb2022
Cyclerion Therapeutics and Tersan Pharmaceuticals Ltd Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment
May2021
Tersan appoints pharmaceutical industry drug development veteran
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas
May2021
Tersan announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases.
May2021
Tersan Announces Appointment of Accomplished Business and Strategy Executive, Kia Motesharei to its Board of Directors.
Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.
Jul2016
Tersan Pharmaceuticals Ltd joins the Healthcare Data Institute
Tersan is pleased to announce that the company has joined the Healthcare Data Institute. The Healthcare Data Institute is the first international think tank dedicated to Big Data in the health sector. An Orange Healthcare initiative, the Healthcare Data Institute was launched in partnership with other companies representative of the Big Data health ecosystem: […]
Jul2016
Pharma Boardroom interview with Mohammad Afshar
Interview with Mohammad Afshar – CEO, Tersan Pharmaceuticals Ltd, France, 12 July 2016 Mohammad Afshar, CEO of Tersan Pharmaceuticals Ltd, shares his insights on the importance of decision support tools, big data’s impact on the healthcare industry, and the need to translate this data into the production of real products. He also discusses the challenges he faced […]
May2016
Tersan Science Day (Paris | May 9)
Tersan hosted their regular Science Day this week – a 1-day symposium in Paris on advances in machine learning and artificial intelligence, chaired by Dr Jean Sallantin, Director of Research at the CNRS LIRMM (Laboratoire d’Informatique, de Robotique et de Micro-électronique de Montpellier) and Scientific Advisor to Tersan. As ever, this was a stimulating […]
Apr2016
NoFinishLine Paris 2016 (Paris | April 13)
The Tersan Running Team are pleased to participate in the popular NoFinishLine Paris 2016 charitable fun run event in support of sick and homeless children. Tersan Running Team at NoFinishLine Paris 2016 (Left to right): Sébastien Vaucouleur, Isabelle Chaduteau, Dan Manak, Mohammad Afshar, Yannic Tognetti, Frédéric Parmentier (11254), David Morley, Vincent Récamier, Julie Miralves, […]